Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New IVD Product is Designed to Improve Prevention and Control of GBS in Newborns

Published: Wednesday, March 28, 2012
Last Updated: Wednesday, March 28, 2012
Bookmark and Share
BD MAX™ GBS assay receives FDA clearance and CLIA moderate complexity test categorization.

BD (Becton, Dickinson and Company) has announced that the U.S. Food and Drug Administration (FDA) clearance of the BD MAX™ Group B Streptococcus (GBS) Assay and Clinical Laboratory Improvement Amendments (CLIA) moderate complexity test categorization on the second-generation BD MAX™ System.  The BD MAX GBS Assay is an in vitro diagnostic (IVD) test for detection of GBS DNA in Lim Broth cultures - enabling laboratories to comply with the 2010 CDC guidelines for GBS screening.

The BD MAX GBS Assay is the only automated IVD method for polymerase chain reaction (PCR) detection of GBS from Lim Broth with a moderate complexity test categorization.  The assay provides an easy-to-use, cost-effective method for laboratories seeking access to a molecular method and optimized resource utilization for GBS testing. BD MAX is the first and only automated, bench-top molecular system designed to perform a broad range of molecular testing, offering unmatched flexibility and versatility.

"FDA clearance of the BD MAX GBS Assay on the second-generation BD MAX System moves BD closer to our goal of providing a next-generation molecular testing system designed to offer and accommodate a broad range of assays," said Gregory Meehan, Vice President, BD Diagnostics – Diagnostic Systems, Molecular Diagnostics. "By simplifying the testing for GBS colonization status, the BD MAX GBS Assay can support improved prevention and control of GBS infections in newborns."

GBS is the leading infectious cause of morbidity and mortality among infants in the United States. The Centers for Disease Control and Prevention estimates that in recent years GBS has caused approximately 1,200 cases of early-onset invasive disease per year; approximately 70 percent of cases are among babies born at term (37 weeks gestation or more).  Screening for colonization late in gestation can identify women who are likely to be colonized with GBS at the time of delivery.

According to Meehan, clearance and categorization of the BD MAX GBS Assay as moderate complexity are important milestones. As we work to develop methicillin-resistant Staphylococcus aureus and Clostridium difficile assays in the months ahead, and additional assays in the years ahead, we believe the BD MAX System is well positioned to potentially be a vital resource for the widest possible range of laboratory testing needs.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BD Receives FDA Clearance for Gastroenteritis Test
The FDA-cleared BD MAX™ Enteric Bacterial Panel for use on the BD MAX System.
Monday, May 12, 2014
BD Collaborates with CME Medical
Collaboration to increase coverage in the UK and Ireland and to provide expanded specialist support to its growing Saf-T-Intima™ customer base.
Sunday, January 12, 2014
BD Announces Approval of Safety Integrated IV Catheter System for Subcutaneous Therapy in Europe
BD Saf-T-Intima™ increases patient comfort and in-dwell times while enabling cost savings and reducing the risk of sharps injuries and infection.
Tuesday, July 23, 2013
BD Helps to Support the Implementation of New Sharps Instruments in Healthcare Regulations
Legislation in place to protect healthcare workers from sharps injuries as a result of new EU Directive on sharps injury prevention.
Thursday, June 13, 2013
BD Acquires Sirigen Group Limited
Expands BD Biosciences' life science research reagent platform.
Wednesday, September 05, 2012
BD Diagnostics and Bruker Collaborate to Improve Microbial Identification and Antimicrobial Susceptibility Testing
BD Diagnostics and Bruker Daltonics Inc. have announced an international co-development and co-marketing collaboration that will promote an emerging, integrated approach to bacterial and fungal identification and antimicrobial susceptibility testing.
Friday, February 11, 2011
BD Biosciences to Expand Manufacturing in Durham, North Carolina
The expansion of Treyburn facility will consolidate and increase U.S. manufacturing for BD Biosciences’ Discovery Labware product line.
Monday, May 14, 2007
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!